131I-MIBG |
Phase II |
50 |
22 |
(5252. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27(25):4162-8, http://dx.doi.org/10.1200/JCO.2008.21.3496. http://dx.doi.org/10.1200/JCO.2008.21.34...
) |
90Y-DOTATOC |
Phase II |
25 |
8 |
(5353. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334-40.) |
177Lu-DOTATOC |
Phase II |
12 |
17 |
(5454. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47(10):1599-606, http://dx.doi.org/10.1080/02841860701441848. http://dx.doi.org/10.1080/02841860701441...
) |
Cyclophosphamide and dacarbazine
|
Retrospective |
52 |
25 |
(5555. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 2012;118(11):2804-12, http://dx.doi.org/10.1002/cncr.26577. http://dx.doi.org/10.1002/cncr.26577...
) |
Cyclophosphamide, vincristine and dacarbazine |
Retrospective |
17 |
47 |
(5656. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer. 2013;4(2):103-10, http://dx.doi.org/10.1007/s12672-013-0133-2. http://dx.doi.org/10.1007/s12672-013-013...
) |
Temozolomide |
Retrospective |
15 |
33 |
(5757. Hadoux J, Favier J, Scoazec JY, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014;135(11):2711-20, http://dx.doi.org/10.1002/ijc.28913. http://dx.doi.org/10.1002/ijc.28913...
) |
Everolimus |
Phase II |
7 |
0 |
(5959. Oh DY, Kim TW, Park YS, Shin SJ, Shin SH, Song EK, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer. 2012;118(24):6162-70, http://dx.doi.org/10.1002/cncr.27675. http://dx.doi.org/10.1002/cncr.27675...
) |
Sunitinib |
Retrospective |
17 |
18 |
(6060. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab. 2012;97(11):4040-50, http://dx.doi.org/10.1210/jc.2012-2356. http://dx.doi.org/10.1210/jc.2012-2356...
) |